Active	Status	Sponsor type	Region	Phase	Filter
10 Active 3 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dunn, Monica
SKNJCT-002, NCT04928222: Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)	Active, not recruiting	1/2	25	US	Doxorubicin-containing MNA, Placebo-containing MNA	SkinJect, Inc.	Basal Cell Carcinoma	12/23	06/24
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma	Recruiting	N/A	86	Canada, US, RoW	DaRT seeds, DaRT	Alpha Tau Medical LTD.	Recurrent Squamous Cell Carcinoma	12/25	12/25
Rosenbluth, Benjamin
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma	Recruiting	N/A	86	Canada, US, RoW	DaRT seeds, DaRT	Alpha Tau Medical LTD.	Recurrent Squamous Cell Carcinoma	12/25	12/25
Gamez, Mauricio E
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma	Recruiting	N/A	86	Canada, US, RoW	DaRT seeds, DaRT	Alpha Tau Medical LTD.	Recurrent Squamous Cell Carcinoma	12/25	12/25
Desai, Alpesh
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma	Recruiting	N/A	86	Canada, US, RoW	DaRT seeds, DaRT	Alpha Tau Medical LTD.	Recurrent Squamous Cell Carcinoma	12/25	12/25
D'Andrea, Mark
NCT05894577: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)	Completed	3	1453	US	Placebo, Montelukast	Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center	Covid19	07/23	01/24
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications	Completed	3	10956	US	Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin	Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center	Covid19	04/24	04/24
NCT06042855: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)	Completed	3	3214	US	Placebo, Metformin	Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center	Covid19	06/24	11/24
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma	Recruiting	N/A	86	Canada, US, RoW	DaRT seeds, DaRT	Alpha Tau Medical LTD.	Recurrent Squamous Cell Carcinoma	12/25	12/25
Ko, Lydia M
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma	Recruiting	N/A	86	Canada, US, RoW	DaRT seeds, DaRT	Alpha Tau Medical LTD.	Recurrent Squamous Cell Carcinoma	12/25	12/25